Maxim Group Thinks Bellerophon’s Stock is Going to Recover
Maxim Group analyst Jason McCarthy maintained a Buy rating on Bellerophon (BLPH) on July 18 and set a price target of $2. The company’s shares closed on Friday at $0.65, close to its 52-week low of $0.47.
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -20.5% and a 24.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Bellerophon has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.79 and a one-year low of $0.47. Currently, Bellerophon has an average volume of 186.7K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.